Metformin and lung cancer

Abstract

Metformin, a commonly used anti-diabetic drug has emerged as a potential anti-cancer drug. Over the last few years, a mass of epidemiologic, outcomes and preclinical data has emerged demonstratic the potential clinical relevance and the mechanistic basis of the anti-cancer activity of this well tolerated drug in lung cancer. This review article summarizes this evidence that supports the trial of this drug in in lung cancer.

Beyond renoprotective impact; ameliorative effects of metformin on malignancies

“…During the last few years, few reports on the association of lung cancer with metformin have been published. These reports are evidence from some epidemiological reports, in-vitro and in-vivo studies and mechanistic examinations (17). However, some other studies detected metformin prevents lung carcinoma development and causes cell death of lung carcinoma (19).…”

“…In another investigation, among 68 019 postmenopausal females that were examined in long-time of 11.8 years, 3273 occurrences of invasive breast cancer were identified (16). Diabetic females taking metformin had lower breast cancer incidence, while females taking other diabetic drugs had a slightly upper incidence of breast cancer in contrast with non-diabetic females (17). The sensitivity to insulin and rising blood glucose levels decrease by metformin administration via preventing of gluconeogenesis in liver and increase glucose uptake in skeletal muscle.…”